Figure 5.

Protective Effect of Anti-α-Gal Abs

(A) Relative absorbance of anti-α-gal Abs (Mean ± SD) in serial serum dilutions from nonimmunized (NI) or rRBCM-immunized (I) α1,3Gt^−/− mice (two experiments; n = 10).

(B) Incidence of blood stage infection (%) in specific immune component-deleted α1,3Gt^−/− mice immunized (I) or not (NI) as in (A) and exposed to PbA^EEF1a-GFP-infected mosquitoes (3–7 experiments; n = 13–41).

(C) Incidence of blood stage of infection (%) in α1,3Gt^−/− mice after passive transfer of anti-α-gal Abs versus controls (no passive transfer; ctr.) exposed to PbA^EEF1a-GFP-infected mosquitoes (4–7 experiments; n = 19–32).

(D) C3 deposition in PbA^Hsp70-GFP sporozoites not exposed (ctr.) or exposed to anti-α-gal Abs plus mouse complement (C). Representative of three independent experiments.

(E) Incidence of blood stage of infection (%) in α1,3Gt^−/−C3^−/− mice after passive transfer of anti-α-gal IgM (μ), IgG2b (γ2b), or IgG3 (γ3) Abs versus controls (ctr.; no passive transfer) not receiving Abs, exposed to PbA^EEF1a-GFP-infected mosquitoes (four experiments; n = 21–37).

(F) Same as (E) in PMN-depleted α1,3Gt^−/− mice (four experiments; n = 15–25).

See also Figures S5 and S6.